PTC Therapeutics, a US-based drugs developer for muscles, plans to float on the Nasdaq stock exchange with a market capitalisation of about $322m. PTC plans to offer 6.9 million shares at between $13 and $16 each. PTC posted a $26m net loss on $34m in revenue for last year, compared to $30m in net income…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
